Universal flu vaccine: Vaccitech initiates Phase 2b clinical studies for vaccine candidate
by Press Release from Outbreak News Today on (#4GHRP)
Vaccitech Ltd. announced that it has administered its pandemic universal influenza A vaccine MVA-NP+M1 (VTP-100) to the first participants in a Flu 010 study - a Phase 2b, randomised, double-blind, placebo controlled, influenza challenge study being conducted in Antwerp, Belgium. In this trial, approved by both the U.S. Food and Drug Administration and Belgium Regulatory ["]
The post Universal flu vaccine: Vaccitech initiates Phase 2b clinical studies for vaccine candidate appeared first on Outbreak News Today.